Labcorp Holdings Inc. Q4 2025 Earnings Call Summary

Performance in 2025 was driven by a 7% top-line increase and 13% adjusted EPS growth, underpinned by deepening health system partnerships that contributed over $1 billion in revenue over three years.
Esoteric and specialty testing achieved double-digit growth, serving as a high-margin engine that captures broader routine testing volume once physicians adopt Labcorp for complex diagnostics.
The successful integration of Invitae has expanded genetic testing capabilities, with management now viewing it as a fully embedded component of their specialty portfolio growing 2-3x faster than the market.
Central Laboratory strength is attributed to high utilization in oncology, neurology, and cardiometabolic clinical trials, supported by a global footprint capable of standardized testing across 100 countries.
Operational efficiency is being driven by AI-powered solutions in pathology and microbiology, alongside the implementation of Roche’s fully automated mass spectrometry solution.
Early Development (ED) faced headwinds, leading to a strategic decision to streamline the business by $50 million in annual revenue to improve utilization and segment profitability.

Management expects 2026 enterprise revenue growth of 5.4% at the midpoint, with adjusted EPS growth of approximately 9% and continued margin expansion across both segments.
The 2026 guidance assumes the PAMA delay remains in effect through the end of the year, though management continues to advocate for permanent reform via the RESULTS Act.
Biopharma Laboratory Services (BLS) margins are expected to expand more significantly than Diagnostics in 2026, driven by Central Lab growth and the completion of ED streamlining by Q2.
Capital expenditures are projected to rise to 4% of revenue to fund a new 500,000-square-foot central laboratory and kit production facility to support long-term clinical trial demand.
Revenue guidance incorporates a 30 basis point headwind to diagnostic volume due to the anticipated expiration of ACA tax credits.

The retirement of two key executives, Mark Schroeder (COO) and Sandy Van der Vaart (Legal), is effective April 1, with successors already appointed via a formal succession plan.
A Q4 organic volume dip was attributed to lower referrals from a specific consumer genetic client facing financial challenges and minor weather impacts, both viewed as non-recurring.
Management is consolidating Early Development capacity rather than waiting for a market rebound, shifting focus to higher-utilization sites to protect segment margins.
Strategic M&A remains a priority with a robust pipeline, though management noted that state-level approval processes are increasingly extending transaction timelines.